Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing and commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory...
Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing and commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory...
- ASSET ON STRONG LEVEL OF DEMAND - STRONG PRODUCT LAUNCH - GOOD CASH AT BANK TO SUPPORT NEW PRODUCT GROWTH AND MARKETING STRATEGIES. - NET PROFIT MARGINS IMPROVED OVER THE LAST 3 QTRS. - ASSET SHOULD SEE IMPROVED EARNINGS INTO 2021 GOOD RR.
EPZM ran quickly out of a very short-term bottom with High Frequency Trader action. High Frequency Trader algos are focused on 3 major industries at this time. This is creating opportunities for retail Swing and Day Traders who can enter with the Professional Traders, who are setting up for the High Frequency Trader algo triggers.
Hi, today we are going to talk about Epizyme and its current landscape. Epizyme is poised to receive increasing attention from the market as relevant events are taking place. The clinical-stage biopharmaceutical company received unanimous approval from the FDA for its cancer drug Tazemetostat for the treatment of patients with epithelioid sarcoma. Amid the...
NASDAQ: #Epizyme | $EPZM looks like an EASY SHORT! All 5 waves appear to be in! Expect a BIG PULLBACK come Monday!